9 reports of this reaction
1.6% of all GLYBURIDE AND METFORMIN HYDROCHLORIDE reports
#15 most reported adverse reaction
OEDEMA PERIPHERAL is the #15 most commonly reported adverse reaction for GLYBURIDE AND METFORMIN HYDROCHLORIDE, manufactured by Aurobindo Pharma Limited. There are 9 FDA adverse event reports linking GLYBURIDE AND METFORMIN HYDROCHLORIDE to OEDEMA PERIPHERAL. This represents approximately 1.6% of all 579 adverse event reports for this drug.
Patients taking GLYBURIDE AND METFORMIN HYDROCHLORIDE who experience oedema peripheral should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OEDEMA PERIPHERAL is a less commonly reported adverse event for GLYBURIDE AND METFORMIN HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to oedema peripheral, the following adverse reactions have been reported for GLYBURIDE AND METFORMIN HYDROCHLORIDE:
The following drugs have also been linked to oedema peripheral in FDA adverse event reports:
OEDEMA PERIPHERAL has been reported as an adverse event in 9 FDA reports for GLYBURIDE AND METFORMIN HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
OEDEMA PERIPHERAL accounts for approximately 1.6% of all adverse event reports for GLYBURIDE AND METFORMIN HYDROCHLORIDE, making it a notable side effect.
If you experience oedema peripheral while taking GLYBURIDE AND METFORMIN HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.